Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473761 | 0.93 | S1PR1 (0.41) | KMOPIN1SCDBRD4 | |
| SCHEMBL3350638 | 0.91 | PIN1 (0.45) | KMOPIN1SCDGRIN1GRIN2B | |
| SCHEMBL3474561 | 0.88 | KMO (0.41) | KMOPIN1CFTRSCDP2RX3 | |
| SCHEMBL3350646 | 0.87 | ALDH1A1 (0.42) | PIN1 | |
| SCHEMBL3376265 | 0.87 | GRIN2B (0.41) | KMOBRD4GRIN1GRIN2B | |
| SCHEMBL3403522 | 0.86 | SCD (0.42) | KMOSCDBRD4GRIN1GRIN2B | |
| SCHEMBL3472626 | 0.86 | PTGDR2 (0.43) | KMOSCDGCGR | |
| SCHEMBL3346223 | 0.84 | PIN1 (0.46) | PIN1 | |
| SCHEMBL15147639 | 0.83 | PIN1 (0.43) | PIN1GRIN1GRIN2B | |
| SCHEMBL3476237 | 0.83 | PIN1 (0.43) | KMOJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | claimed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | claimed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | KMO 1233/4885JAK2 441/4885JAK1 3240/4885 |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | KMO 1233/4885JAK2 441/4885JAK1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.